Objective

2

To observe the clinical efficacy as well as anti-inflammatory and anti-fibrosis mechanism of Yishen Tongluo decoction in the treatment of chronic glomerulonephritis （CGN） with spleen and kidney Qi deficiency and blood stasis syndrome.

Method

2

According to the random number table method， one hundred and twenty patients were divided into control group （60 cases） and observation group （60 cases）. The two groups were given oral valsartan capsules， 160 mg/time， 1 time/day， and dipyridamole tablets orally， 50 mg/time， 3 times/day. Patients in control group additionally took Wubi Shanyao pills orally， 9 g/time， 2 times/day， while patients in observation group additionally took Yishen Tongluo decoction orally， 1 dose/day. Both groups were treated continuously for four months. Before and after treatment， 24 h urine total protein （24 h UTP）， creatinine （SCr）， urea nitrogen （BUN）， serum cystatin C （CysC）， tumor necrosis factor-

α

（TNF-

α

）， interleukin-6 （IL-6）， IL-17， interferon-

γ

（IFN-

γ

）， transforming growth factor-

β

1

（TGF-

β

1

）， connective tissue growth factor （CTGF）， matrix metalloproteinase-9 （MMP-9）， tissue inhibitor of metalloproteinases （TMP-1） and hypoxia inducible factor-1

α

（HIF-1

α

） levels were detected in both groups. The scores of spleen and kidney Qi deficiency and blood stasis syndrome were graded. Urine protein， and urine red blood cells （urinary RBC） were monitored.

Result

2

The 24 h UTP， SCr， BUN and CysC levels of the observation group were lower than those of the control group （

P

<

0.01）. The score of spleen and kidney Qi deficiency and blood stasis syndrome in the observation group was lower than that in the control group （

P

<

0.01）. The levels of TNF-

α

， IL-6， IL-17 and IFN-

γ

in the observation group were lower than those in the control group （

P

<

0.01）. The levels of TGF-

β

1

， CTGF， TMP-1 and HIF-1

α

in the observation group were lower than those in the control group （

P

<

0.01）. While MMP-9 level was higher than that in control group （

P

<

0.01）. The clinical effective rate was 88.33% （53/60） in the observation group， higher than 73.33% （44/60） in the control group （

<math id="M2"><msup><mrow><mi>χ</mi></mrow><mrow><mn mathvariant="normal">2</mn></mrow></msup></math>

http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=16684991&type=

http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=16684988&type=

3.30200005

3.64066648

=4.356，

P

<

0.05）.

Conclusion

2

On the basis of conventional Western medicine treatment， Yishen Tongluo decoction in the treatment of CGN patients with spleen and kidney Qi deficiency and blood stasis syndrome can reduce proteinuria， and improve traditional Chinese medicine （TCM） syndromes， with anti-inflammatory and anti-kidney fibrosis effects. Thereby， it plays a role in protecting renal function and delaying the malignant progression of renal function， with high clinical efficacy and value of clinical use.